Edition:
United States

Neurocrine Biosciences Inc (NBIX.O)

NBIX.O on Nasdaq

84.10USD
12:06pm EST
Change (% chg)

$-1.32 (-1.55%)
Prev Close
$85.42
Open
$85.53
Day's High
$86.05
Day's Low
$82.63
Volume
218,394
Avg. Vol
972,809
52-wk High
$91.82
52-wk Low
$39.21

Latest Key Developments (Source: Significant Developments)

Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids
Wednesday, 21 Feb 2018 08:00am EST 

Feb 21 (Reuters) - Abbvie Inc ::ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS.PHASE 3 ELARIS UF-I STUDY (M12-815) OF ELAGOLIX MET ITS PRIMARY ENDPOINT.RESULTS DEMONSTRATED ELAGOLIX, IN COMBINATION WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO.PHASE 3 ELARIS UF-I STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.001) AT MONTH SIX.  Full Article

Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data
Wednesday, 14 Feb 2018 04:01pm EST 

Feb 14 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSON'S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA.NEUROCRINE BIOSCIENCES INC - NEUROCRINE WILL PROCEED WITH PLANS TO FILE NDA FOR OPICAPONE DURING FIRST HALF OF 2019.NEUROCRINE BIOSCIENCES INC - U.S. FDA HAS PROVIDED GUIDANCE ON REGULATORY PATH FORWARD TO SUPPORT NDA FOR OPICAPONE.NEUROCRINE BIOSCIENCES INC - NEUROLOGY DIVISION OF FDA HAS NOT REQUESTED CO TO CONDUCT AN ADDITIONAL PHASE III STUDY FOR OPICAPONE PRIOR TO NDA FILING.  Full Article

Neurocrine Biosciences Reports Q4 Earnings Per Share $0.07
Tuesday, 13 Feb 2018 04:01pm EST 

Feb 13 (Reuters) - Neurocrine Biosciences Inc ::NEUROCRINE BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES INVESTOR UPDATE FOR 2018.Q4 EARNINGS PER SHARE $0.07.Q4 REVENUE $94.5 MILLION.NEUROCRINE BIOSCIENCES- REVENUE MILESTONES UNDER ABBVIE AGREEMENT FOR 2018 EXPECTED TO BE $40 MILLION CONTINGENT ON FDA APPROVAL OF ELAGOLIX FOR ENDOMETRIOSIS.‍ONGOING OPERATING EXPENSES FOR 2018 SHOULD APPROXIMATE $365 MILLION TO $395 MILLION​.  Full Article

Neurocrine Biosciences appoints Matt Abernethy as CFO
Monday, 20 Nov 2017 04:01pm EST 

Nov 20 (Reuters) - Neurocrine Biosciences Inc ::Neurocrine Biosciences appoints Matt Abernethy as chief financial officer.Neurocrine Biosciences Inc - announced that Matt Abernethy is joining executive management team as chief financial officer​.  Full Article

Neurocrine Biosciences reports Q3 loss per share $0.13
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences reports third quarter 2017 results.Q3 loss per share $0.13.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Says net product sales of $45.8 million for three months ended September 30, 2017​.  Full Article

Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix
Friday, 27 Oct 2017 07:00am EDT 

Oct 27 (Reuters) - Abbvie Inc :Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain.Abbvie inc - ‍expects PDUFA date for FDA to complete its review will be in Q2 2018​.  Full Article

Neurocrine initiates Phase IIb clinical study of Ingrezza
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Neurocrine Biosciences Inc :Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome.Neurocrine Biosciences Inc - ‍top-line data from study is expected in late 2018​.  Full Article

Neurocrine granted FDA orphan drug designation for Valbenazine
Monday, 23 Oct 2017 04:57pm EDT 

Oct 23 (Reuters) - Neurocrine Biosciences Inc :Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome.  Full Article

Neurocrine Biosciences says David-Alexander Gros resigns as COO and interim CFO of co
Thursday, 19 Oct 2017 05:52pm EDT 

Oct 20 (Reuters) - Neurocrine Biosciences Inc :Neurocrine Biosciences Inc - ‍on Oct. 18, David-Alexander C. Gros resigned as president, COO and interim CFO of co, effective as of Oct. 19 - SEC filing.Neurocrine Biosciences Inc - ‍in connection with resignation of Gros, effective Oct. 19, Kevin C. Gorman​ was appointed as company's interim CFO.  Full Article

Neurocrine announces FDA approval of 80 mg Ingrezza
Thursday, 5 Oct 2017 07:00am EDT 

Oct 5 (Reuters) - Neurocrine Biosciences Inc : :Neurocrine announces FDA approval of 80 mg Ingrezza® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).Says ‍80 mg capsule of Ingrezza will be available for patients within two weeks through a select pharmacy network​.  Full Article

BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data

* NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSON'S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA